Results 171 to 180 of about 101,292 (266)

Clinical, surgical, and endocrine outcome following treatment of posterior pituitary tumors: a retrospective cohort study. [PDF]

Pituitary
Kremenevski N, Schnell O, Coras R, Buchfelder M, Hore N.   +4 more
europepmc   +1 more source

ERDHEIM‐Chester Disease: Two Fatal Cases With Unusual Presentations

Clinical Case Reports, Volume 14, Issue 6, June 2026.
Fluorodeoxyglucose positron emission tomography‐computed tomography (FDG PET‐CT) demonstrated markedly increased metabolic activity in serosal surfaces including pericardium, pleura, and renal fascia, as well as diffuse uptake along vascular walls, particularly the entire aorta.
Ribero‐Vargas Daniel Andres, C. Álvarez Payares José, Murillo‐Pérez Juliana   +2 more
wiley   +1 more source

Aggressive pituitary tumors and pituitary carcinomas: Definition, management, and overview for clinical practice. [PDF]

Neurooncol Adv
Calvanese F, Jannelli G, Feuvret L, Vasiljevic A, Manet R, Sergeant C, Raverot G, Jouanneau E.   +7 more
europepmc   +1 more source

Hepatocyte growth factor/c‐Met signaling axis in human diseases: Mechanistic insights and therapeutic potential

Journal of Cell Communication and Signaling, Volume 20, Issue 2, June 2026.
Figure 1 visually summarizes the core biological functions and therapeutic potential of the HGF/c‐Met signaling axis. Abstract Hepatocyte growth factor (HGF) is a multifunctional cytokine that activates the tyrosine kinase activity of its specific receptor, c‐Met (mesenchymal–epithelial transition factor).
Hongqin Sun, Hao Shu, Qian Zhang, Jishan Zheng, Yunyan Ma, Dengwang Chen, Jidong Zhang, Tao Song   +7 more
wiley   +1 more source

Machine learning method based on radiomics help differentiate posterior pituitary tumors from pituitary neuroendocrine tumors and craniopharyngioma. [PDF]

Sci Rep
Liu Y, Zhou Y, Zhou C, Wang Z, Fan Z, Tang K, Chen S.   +6 more
europepmc   +1 more source

More Than a Question of Correlation: Characterization of the Evidentiary Basis for Biomarker Surrogates Used in European Marketing Authorizations

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1522-1536, June 2026.
Traditionally, clinical outcomes measuring how a patient feels, functions, or survives are preferred endpoints in clinical trials; however, some may take a long time to manifest in slowly developing diseases. Biomarkers, if properly validated, can serve as surrogate endpoints, acting as substitutes for clinical outcomes.
Renske Johanna Grupstra, Viktoriia Starokozhko, Elisabeth Bakker, Anna Maria Gerdina Pasmooij, Peter Gerardus Maria Mol   +4 more
wiley   +1 more source

Whole genome sequencing and single-cell transcriptomics identify KMT2D inactivation as a potential new driver for pituitary tumors: a case report. [PDF]

BJC Rep
Brunner M, Meylan-Merlini J, Muriset M, Oreshkov S, Messina A, Messerer M, Daniel R, Hewer E, Brouland JP, Santoni F.   +9 more
europepmc   +1 more source

Bibliometric Analysis of Cubebenes and Related Sesquiterpenes: Natural Occurrence, Biosynthesis, Pharmacological Activities, and In‐Silico‐Based Future Therapeutic Potential

eFood, Volume 7, Issue 3, June 2026.
Cubebene‐related sesquiterpenes, found across diverse biological sources, exhibit promising pharmacological activities, including anti‐inflammatory, neuroprotective, and anticancer effects. This review highlights their molecular diversity, ADME profiles, and predicted multitarget interactions, underscoring their therapeutic relevance and potential in ...
Khadija Boualam, Ahmet B. Ortaakarsu, Sohaib Khatib, Mohamed A. Farag, Mansour Sobeh   +4 more
wiley   +1 more source

Preoperative Prediction of Non-functional Pituitary Neuroendocrine Tumors and Posterior Pituitary Tumors Based on MRI Radiomic Features. [PDF]

J Imaging Inform Med
Jin S, Xu Q, Sun C, Zhang Y, Wang Y, Wang X, Guan X, Li D, Li Y, Zhang C, Jia W.   +10 more
europepmc   +1 more source